Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03635489 |
| Consolidated Lead Sponsor | Roche / Genentech |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 100 participants (ACTUAL) |
| Registered Start Date | 2018-08-15 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| The First Hospital of Jilin University | Changchun, China | Open Hospital Dossier -> |
| Jilin Cancer Hospital | Changchun, China | Open Hospital Dossier -> |
| Xiangya Hospital Central South University | Changsha, China | Open Hospital Dossier -> |
| Fujian Cancer Hospital | Fuzhou, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.